Metronomics: Potential Social Impact and New Business Models to Improve Availability of Cancer Treatments

  • Yuliya Snihur
  • Eddy Pasquier
  • Graciela Scharovsky
  • Nicolas Andre
Chapter

Abstract

Over the last 15 years, metronomic chemotherapy (MC) alone or combined with drug repositioning (DR) has gradually gained interest from cancer researchers and clinicians. Metronomics, the combination of MC and DR, can provide inexpensive, easy to administer and non-toxic treatments for cancer patients, while introducing innovative mechanisms of anti-tumour action.

In this article, we explore how the use of metronomics can deliver important social gain by allowing to treat patients for whom therapeutic options would be otherwise limited or absent. Thus, patients living in low- and middle-income countries (LMICs) can benefit from metronomics to the same extent as patients living in high-income countries (HICs). In both settings, frail patients can also take advantage of the low toxicity associated with metronomics. Here, we focus on new business models that could help in bridging the gap between LMICs and HICs with regard to anticancer treatments through the use of metronomics. In particular, we analyse the principles explaining how business model innovation can make cancer therapies available and affordable to patients with limited resources. Overall, we argue that new business models are essential to the optimal development of metronomics and the combination of business model innovation with metronomics can help fight cancer in LMICs.

Keywords

Toxicity Arsenic Marketing Sarcoma Methotrexate 

References

  1. 1.
    De Lima Lopes G Jr, de Souza J, Barrios C (2010) Access to cancer medications in low-and middle-income countries. Nat Rev Clin Oncol 10:314–322CrossRefGoogle Scholar
  2. 2.
    Howlader N et al. (eds) (2010) SEER cancer statistics review, 1975–2007 (Vintage 2009 populations), National Cancer Institute [online], http://seer.cancer.gov/csr/1975_2009_pops09/
  3. 3.
    André N, Banavali S, Snihur Y, Pasquier E (2013) Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14:e239–e248PubMedCrossRefGoogle Scholar
  4. 4.
    Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455–465PubMedCrossRefGoogle Scholar
  5. 5.
    Varmus H, Trimble EL (2011) Integrating cancer control into global health. Sci Transl Med 3:101cm28PubMedCrossRefGoogle Scholar
  6. 6.
    WHO (2011) United Nations high level meeting on noncommunicable disease prevention and control. WHO, New YorkGoogle Scholar
  7. 7.
    The General Assembly (2011) Resolution 66/2: political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases. United Nations, New YorkGoogle Scholar
  8. 8.
    LiveStrong foundation and American Cancer Society, 2012 (2010) The global economic cost of cancer. The American Cancer Society [online]. http://www.cancer.org/aboutus/globalhealth/global-economic-cost-of-cancer-report
  9. 9.
    Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer PJ (2011) Role of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol 29:3097–3102PubMedCrossRefGoogle Scholar
  10. 10.
    Dikshit R, Gupta PC, Ramasundarahettige C et al (2012) Cancer mortality in India: a nationally representative survey. Lancet 379:1807–1816PubMedCrossRefGoogle Scholar
  11. 11.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  12. 12.
    WHO. Model list of essential medicines. 17th model list 2011. http://www.who.int/medicines/publications/essentialmedicines/en/index.html
  13. 13.
    Kerr DJ, Midgley R (2010) Can we treat cancer for a dollar a day? Guidelines for low income countries. N Engl J Med 363:801–803PubMedCrossRefGoogle Scholar
  14. 14.
    Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRefGoogle Scholar
  15. 15.
    André N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7:385–394PubMedCrossRefGoogle Scholar
  16. 16.
    Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683PubMedCrossRefGoogle Scholar
  17. 17.
    Perroud HA, Rico MJ, Alasino CM, Queralt F, Pezzotto SM, Rozados VR, Scharovsky OG (2013) Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 9:451–462PubMedCrossRefGoogle Scholar
  18. 18.
    Činčárová L, Zdráhal Z, Fajkus J (2013) New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs 22:1535–1547PubMedCrossRefGoogle Scholar
  19. 19.
    Moon H, Hill MM, Roberts MJ, Gardiner RA, Brown AJ (2014) Statins: protectors or pretenders in prostate cancer? Trends Endocrinol Metab 25:188–196. doi: 10.1016/j.tem.2013.12.007, pii: S1043-2760(13)00215-4PubMedCrossRefGoogle Scholar
  20. 20.
    Pernicova I, Korbonits M (2014) Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10:143–156. doi: 10.1038/nrendo.2013.256 PubMedCrossRefGoogle Scholar
  21. 21.
    Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA (2013) Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18:163–173PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kim J, Lee JJ, Kim J, Gardner D, Beachy PA (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A 107:13432–13437PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, Ashikaga T, Kamen BA, Homans AC, Slavik MA, Lenox SR, Higgins TJ, Ferguson WS (2011) A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 33:25–30PubMedCrossRefGoogle Scholar
  24. 24.
    Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M (2013) β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 108:2485–2494PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Colleoni M, Rocca A, Sandri MT et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80PubMedCrossRefGoogle Scholar
  26. 26.
    Gebbia V, Serretta V, Borsellino N, Valerio MR, GSTU Foundation (2011) Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 78:1125–1130PubMedCrossRefGoogle Scholar
  27. 27.
    Fedele P, Marino A, Orlando L et al (2012) Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 48:24–29PubMedCrossRefGoogle Scholar
  28. 28.
    Fousseyni T, Diawara M, Pasquier E, André N (2011) Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol 33:31–34PubMedCrossRefGoogle Scholar
  29. 29.
    Traore F, Togo B, Pasquier E, Dembélé A, André N (2013) Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. Indian J Cancer 50:250–253PubMedCrossRefGoogle Scholar
  30. 30.
    Banavali S, Singh R, Prasad M et al (2011) Is there a role for a novel maintenance therapy in pediatric patients with AML? Pediatr Blood Cancer 57:770Google Scholar
  31. 31.
    Pai P, Vaidya A, Prabhash K, Banavali S (2011) Oral metronomic chemotherapy in advanced oral squamous cell cancers: a matched pair analysis. Oral Oncol 47:S79 (P17)CrossRefGoogle Scholar
  32. 32.
    André N, Pasquier E (2013) Metronomics in low and middle income countries: India showing the way! Indian J Cancer 50:112–114PubMedCrossRefGoogle Scholar
  33. 33.
    de la Cruz M, Bruera E (2013) Approach to the older patient with cancer. BMC Med 11:218PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10:301–306PubMedCrossRefGoogle Scholar
  35. 35.
    Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G (2010) Metronomic chemotherapy for metastatic prostate cancer: a ‘young’ concept for old patients? Drugs Aging 27:689–696PubMedCrossRefGoogle Scholar
  36. 36.
    Fontana A, Bocci G, Galli L, D’Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A (2010) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 58:986–988PubMedCrossRefGoogle Scholar
  37. 37.
    Mir O, Domont J, Cioffi A et al (2011) Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer 47:515–519PubMedCrossRefGoogle Scholar
  38. 38.
    He S, Shen J, Hong L, Niu L, Niu D (2012) Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol 29:100–106PubMedCrossRefGoogle Scholar
  39. 39.
    Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L (2010) Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 28:684–689PubMedCrossRefGoogle Scholar
  40. 40.
    Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L (2013) Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon 13:e11721PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, Serra C, Sama C, Golfieri R, Gramenzi A, Cucchetti A, Pinna AD, Trevisani F, Biasco G, Italian Liver Cancer (ITA.LI.CA) Group (2013) Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 18:1256–1257PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Zhou F, Ling C, Guo L, Wei W, Li L, Shi H, Hou J (2014) Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leuk Lymphoma [Epub ahead of print]Google Scholar
  43. 43.
    Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D Jr, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B (2013) Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica 98:1147–1153PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Casadesus-Masanell R, Zhu F (2013) Business model innovation and competitive imitation. Strat Manag J 34:464–482CrossRefGoogle Scholar
  45. 45.
    Markides C (2006) Disruptive innovation: in need of better theory. J Prod Innov Manag 23:19–25CrossRefGoogle Scholar
  46. 46.
    Zott C, Amit R, Massa L (2011) The business model: recent developments and future research. J Manag 37(4):1019–1042Google Scholar
  47. 47.
    Amit R, Zott C (2001) Value creation in E-business. Strat Manag J 22(6/7, Special Issue: Strategic Entrepreneurship: Entrepreneurial Strategies for Wealth Creation):493–520Google Scholar
  48. 48.
    Gambardella A, McGahan AM (2010) Business-model innovation: general purpose technologies and their implications for industry structure. Long Range Plann 43:262–271CrossRefGoogle Scholar
  49. 49.
    McGrath RG (2010) Business models: a discovery driven approach. Long Range Plann 43:247–261CrossRefGoogle Scholar
  50. 50.
    Zott C, Amit R (2007) Business model design and the performance of entrepreneurial firms. Org Sci 18:181–199CrossRefGoogle Scholar
  51. 51.
    Zott C, Amit R (2008) The fit between product market strategy and business model: implications for firm performance. Strat Manag J 29:1–26CrossRefGoogle Scholar
  52. 52.
    Brandenburger AM, Stuart HW (1996) Value‐based business strategy. J Econ Manag Strat 5:5–24CrossRefGoogle Scholar
  53. 53.
    Crossan MM, Apaydin M (2010) A multi-dimensional framework of organizational innovation: a systematic review of the literature. J Manag Stud 47:1154–1191CrossRefGoogle Scholar
  54. 54.
    Utterback JM, Abernathy WJ (1975) A dynamic model of process and product innovation. Omega 3(6):639CrossRefGoogle Scholar
  55. 55.
    Birkinshaw J, Hamel G, Mol M (2008) Management innovation. Acad Manage Rev 33:825–845CrossRefGoogle Scholar
  56. 56.
    Teece DJ (2010) Business models, business strategy and innovation. Long Range Plann 43:172–194CrossRefGoogle Scholar
  57. 57.
    Zott C, Amit R (2010) Business model design: an activity system perspective. Long Range Plann 43:216–226CrossRefGoogle Scholar
  58. 58.
    Nelson RR, Winter SG (1982) An evolutionary theory of economic change. Harvard University Press, CambridgeGoogle Scholar
  59. 59.
    Guillén MF (1994) Models of management: work, authority, and organization in a comparative perspective. University of Chicago Press, ChicagoGoogle Scholar
  60. 60.
    Johnson MW, Christensen CM, Kagermann H (2008) Reinventing your business model. Harv Bus Rev 86:58–68Google Scholar
  61. 61.
    Mullins JW, Komisar R (2009) Getting to plan B: breaking through to a better business model. Harvard Business Press, BostonGoogle Scholar
  62. 62.
    Chesbrough H, Rosenbloom RS (2002) The role of the business model in capturing value from innovation: evidence from Xerox Corporation’s technology spin‐off companies. Ind Corporate Change 11:529–555CrossRefGoogle Scholar
  63. 63.
    Anderson J, Markides C (2012) Strategic Innovation at the Base of the Pyramid. Sloan Manag Rev 49(1):83–88Google Scholar
  64. 64.
    Hart SL, Sharma S (2004) Engaging fringe stakeholders for competitive imagination. Acad Manag Exec 18:7–18CrossRefGoogle Scholar
  65. 65.
    Hammond AJ, Kramer WJ, Katz RS, Tran JT, Walker C (2007) The next 4 billion: market size and business strategy at the base of the pyramid. World Resources Institute/International Finance Corporation, Washington, DCGoogle Scholar
  66. 66.
    Casadesus-Masanell R, Ricart JE (2010) From strategy to business models and on to tactics. Long Range Plann 43:195–215CrossRefGoogle Scholar
  67. 67.
    Yunus M, Moingeon B, Lehmann-Ortega L (2010) Building social business models: lessons from the Grameen experience. Long Range Plann 43:308–325CrossRefGoogle Scholar
  68. 68.
    Velayudhan SK, Sundaram MR, Thulasiraj RD (2011) Aravind Eye Care System: providing total eye care to the rural population. Richard Ivey School of Business Case StudyGoogle Scholar
  69. 69.
    Andre N, Guercio B, Pasquier E (2013) Investment in cancer studies in countries of low and middle income. Lancet 382(9893):684PubMedCrossRefGoogle Scholar
  70. 70.
    Benner MJ, Tushman M (2002) Process management and technological innovation: a longitudinal study of the photography and paint industries. Adm Sci Q 47:676–707CrossRefGoogle Scholar
  71. 71.
    Weir SJ, DeGennaro LJ, Austin CP (2012) Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 72:1055–1058PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Yuliya Snihur
    • 1
    • 2
  • Eddy Pasquier
    • 2
    • 3
  • Graciela Scharovsky
    • 2
    • 4
  • Nicolas Andre
    • 2
    • 5
    • 6
  1. 1.University of Toulouse, Toulouse Business SchoolToulouse, Cedex 7France
  2. 2.Metronomics Global Health InitiativeMarseilleFrance
  3. 3.Tumour Biology and Targeting ProgramChildren’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South WalesRandwickAustralia
  4. 4.Instituto de Genética Experimental, Facultad de Ciencias MédicasUniversidad Nacional de RosarioRosarioArgentina
  5. 5.Hematology and Pediatric Oncology DepartmentLa Timone University Hospital of MarseilleMarseilleFrance
  6. 6.Faculty of PharmacyINSERM UMR 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Aix-Marseille UniversityMarseilleFrance

Personalised recommendations